Amendment No. 1 to

EX-4.2(B) 3 dex42b.htm AMENDMENT #1 DATED 12/6/04 TO THIRD AMENDED AND RESTATED RIGHTS AGREEMENT AMENDMENT #1 DATED 12/6/04 TO THIRD AMENDED AND RESTATED RIGHTS AGREEMENT

 

Exhibit 4.2(b)

 

Amendment No. 1 to

Third Amended and Restated Investor Rights Agreement

 

THIS AMENDMENT NO. 1 to the Third Amended and Restated Investor Rights Agreement dated December 6, 2004 (this “Amendment”) amends the Third Amended and Restated Investor Rights Agreement dated May 12, 2004 (the “Future IRA”) by and among Targacept, Inc. (the “Company”) and the holders of shares of the Company’s Series C Convertible Preferred Stock, $0.001 par value per share (“Series C Stock”), Series B Convertible Preferred Stock, $0.001 par value per share (“Series B Stock”), or Series A Convertible Preferred Stock, $0.001 par value per share (“Series A Stock” and, together with the Series C Stock and Series B Stock, “Preferred Stock”) party thereto. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Future IRA.

 

R E C I T A L S:

 

WHEREAS, the Future IRA was entered into in contemplation of an initial public offering of the Company’s common stock in order to amend, effective as of the closing of such initial public offering, the Company’s Second Amended and Restated Investor Rights Agreement dated November 26, 2002, as amended (the “Current IRA”), which is currently in effect; and

 

WHEREAS, by its terms, the Future IRA will not become effective or affect the Current IRA unless and until the prospective initial public offering is completed and will not become effective at all if such initial public offering is not completed on or before December 31, 2004 (the “Trigger Date”); and

 

WHEREAS, Section 3 of the Future IRA provides that the Future IRA may be amended only with the prior written consent of the Company and the holders of a majority of the outstanding Series A Registrable Securities and Series B Registrable Securities and at least 65% of the outstanding Series C Registrable Securities (collectively, the “Required Investors”); and

 

WHEREAS, the prospective initial public offering may not be completed on or before the Trigger Date, and the Company and the undersigned holders of Preferred Stock, constituting the Required Investors, desire to amend the Future IRA as provided herein to extend the Trigger Date;

 

NOW, THEREFORE, the undersigned parties agree as follows:

 

1. Section 2.1(a) of the Future IRA is hereby amended by deleting the first sentence in its entirety and replacing it with the following:

 

“Subject to the other provisions of this Section 2.1, Section 2.8 and Section 2.9, if, at any time or from time to time following the Eligibility Date (but in no event prior to (x) six months after the effective date of the first registration of the Company’s securities on Form S-1 or (y) three months after the effective date of any other registration of the Company’s securities, other than registrations on Form S-4, Form S-8 or comparable or successor forms and other than registrations for the account of selling stockholders on Form S-3 or a comparable or successor form), the Company shall receive a written

 


request (specifying that it is being made pursuant to this Section 2.1) from (i) Holders of at least a majority of the Series A Registrable Securities and Series B Registrable Securities, considered together, or (ii) Holders of Series C Registrable Securities that the Company file a registration statement under the Act covering the registration for offer and sale of (A) in the case of clause (i) above, at least thirty percent (30%) of all Series A Registrable Securities and Series B Registrable Securities, considered together, or (B) in the case of clause (ii) above, at least (1) thirty percent (30%) of all Series C Registrable Securities or (2) a number of Series C Registrable Securities for which the total gross proceeds in a public offering reasonably expected to be received by the requesting Holders is at least $7,500,000, then the Company shall, within ten (10) business days notify in writing all other Holders of such request.”

 

2. Section 9 of the Future IRA is hereby amended by replacing “December 31, 2004” therein with “June 30, 2005.”

 

3. As expressly amended hereby, the Future IRA shall continue in full force and effect.

 

4. For the avoidance of doubt, as used in the Future IRA and the Current IRA, the term “Series C Stock” shall include, without limitation, shares of Series C Stock issued and sold pursuant to the Series C Convertible Preferred Stock Purchase Agreement entered into on or about the date hereof.

 

[signature page follows]

 

2


IN WITNESS WHEREOF, this Amendment No. 1 to the Third Amended and Restated IRA is executed as of the day and year first above written.

 

TARGACEPT, INC.
By:   /s/ J. Donald deBethizy
   

Name:

 

J. Donald deBethizy

   

Title:

 

President & CEO

R.J. REYNOLDS TOBACCO HOLDINGS, INC.
By:   /s/ Charles A. Blixt
   

Name:

 

Charles A. Blixt

   

Title:

 

President

EUCLIDSR PARTNERS, L.P.
By:  

EuclidSr Associates, L.P.,
its general partner

    By:  

/s/ Elaine V. Jones

       

Elaine V. Jones

       

General Partner

EUCLIDSR BIOTECHNOLOGY PARTNERS, L.P.
By:  

EuclidSr Biotechnology Associates, L.P.,
its general partner

    By:  

/s/ Elaine V. Jones

       

Elaine V. Jones

       

General Partner

BURRILL BIOTECHNOLOGY CAPITAL FUND, L.P.
By:  

Burrill & Company (Biotechnology GP), LLC,
its General Manager

    By:  

/s/ G. S. Burrill

       

G. Steven Burrill

       

Managing Member

 

[signatures continue on following page]

 

3


GENAVENT FUND

By:

 

Société Générale Asset Management, S.A.,

its Manager

By:

 

/s/ Ferriere

   

Corinne Ferriere

   

Deputy Head of Private Equity

 

FCPR SGAM AI BIOTECHNOLOGY FUND

Represented by SGAM Alternative Investments, its

management company with a share capital of 35 576

725 euros, having its registered office at 2, place de la Coupole, 92078 Paris – La Défense cedex France,

registered with the Nanterre Trade and Companies

registry under the number B 410 704 571

By:

 

/s/ Ferriere

   

Corinne Ferriere

   

Deputy Head of Private Equity

 

FCPR CDC INNOVATION 2000, a venture

capital fund represented by CDC ENTREPRISES

INNOVATION, its management company

(“Societe de gestion”) with a share capital of

EUR 762,000

By:

 

/s/ T. Laugel

   

Name: T. Laugel

   

Title: Director d’investissement

 

ADVENT PRIVATE EQUITY FUND II,

‘A’ LIMITED PARTNERSHIP

ADVENT PRIVATE EQUITY FUND II,

‘B’ LIMITED PARTNERSHIP

ADVENT PRIVATE EQUITY FUND II,

‘C’ LIMITED PARTNERSHIP

ADVENT PRIVATE EQUITY FUND II,

‘D’ LIMITED PARTNERSHIP

By:

 

Advent Venture Partner, General Partner

   

By:

 

/s/ Patrick Lee

       

Name: Patrick Lee

       

Title: General Partner

 

[signatures continue on following page]

 

4


NOMURA PHASE4 VENTURES LIMITED AS MANAGER ON BEHALF OF INTERNATIONAL PLC AND NOMURA PHASE4 VENTURES LP

By:

 

/s/ Denise Pollard-Knight

   

Name: Denise Pollard-Knight

   

Title: Head of Nomura Phase4 Ventures Ltd.

NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP
By:  

NEA Partners 10, Limited Partnership, General Partner

By:

 

/s/ E. A. Trainor

   

Name: Eugene A. Trainor, III

    Administrative General Partner & Chief Operating Officer
NEA VENTURES, 2002 LIMITED PARTNERSHIP

By:

 

/s/ Pamela J. Clark

   

Pamela J. Clark

   

General Partner

CDIB BIOSCIENCE VENTURES I, INC.

By:

 

/s/ Benny T. Hu

   

Name: Benny T. Hu

   

Title: Chairman

JAFCO G-9(A) VENTURE CAPITAL INVESTMENT LIMITED PARTNERSHIP
By:  

JAFCO CO., LTD., its general partner

By:

 

/s/ Tomio Kezuka

   

Name: Tomio Kezuka

   

Title: Executive Vice President

 

[signatures continue on following page]

 

5


JAFCO G-9(B) VENTURE CAPITAL

INVESTMENT LIMITED PARTNERSHIP

By:

 

/s/ Tomio Kezuka

   

Name: Tomio Kezuka

   

Title: Executive Vice President

 

6